The Best Big Biotech for 2013 DailyFinance Results from a phase 3 study of daclizumab HYP, another multiple sclerosis drug developed in partnership with AbbVie , are expected in 2014. Celgene Celgene provided upbeat product and financial updates. CEO Bob Hugin announced 2012 earnings ... |
